ENANTA PHARMACEUTICALS INC

ENTA stock represents shares of Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company. It trades on the Nasdaq Global Select Market under the ticker symbol ENTA. The stock gives investors exposure to a company focused on developing small-molecule drugs for viral infections and liver diseases. As a biopharmaceutical stock, ENTA's value is tied to its research pipeline, clinical trial outcomes, and regulatory developments.

ENTA's recent stock performance reflects investor reactions to clinical trial updates, pipeline news, and broader biotech market trends. For the latest price changes, including daily moves and period returns, please refer to the current ENTA quote and performance data displayed on this page. Biotech stocks like ENTA can be volatile around data releases and regulatory milestones.

The 52-week range shows the lowest and highest prices at which ENTA has traded over the past year. This range helps investors gauge the stock's volatility and recent trading boundaries. For the current 52-week high and low, please check the latest ENTA data on this page, as these figures change with market activity.

Evaluating ENTA's valuation can be challenging because clinical-stage biotechs often have limited or no product revenue, making traditional metrics like P/E less meaningful. Investors may look at price-to-book, enterprise value, and cash runway, while also assessing pipeline potential and probability-adjusted forecasts. Compare ENTA's valuation to peers in the biotechnology sector and consider its stage of development.

Key risks for ENTA include clinical trial failures, regulatory delays, and competition in antiviral and liver disease research. As a clinical-stage company, ENTA may rely on external financing, and dilution or cash burn could pressure the stock. Additionally, pipeline setbacks or unfavorable trial data can lead to sharp price declines. Broader biotech market sentiment and interest rate changes may also affect ENTA's valuation.

Earnings information for ENTA, including quarterly reports and financial statements, is typically available in the investor relations section of the company's website and in filings with the U.S. Securities and Exchange Commission (SEC). This page may also provide earnings dates and summaries. Reviewing ENTA's income statement, balance sheet, and cash flow statement can help investors understand its financial health and research progress.